ViroPharma Inc.
730 Stockton Drive
Exton,
PA 19341
United States - Map
Phone: 610-458-7300
Fax: 610-458-7380
Web Site: http://www.viropharma.com
| ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Its products include Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains; and Cinryze for the prevention of hereditary angioedema attacks. The companys products in development include Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus disease; and non-toxigenic strains of C. difficile, which is in preclinical stage for the treatment and prevention of CDI. It licensed the third product development candidate, an intranasal formulation of pleconaril, to Schering-Plough for the treatment of picornavirus infections in the U.S. and Canada. It sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. The company has strategic relationships with Eli Lilly and Company, GlaxoSmithKline, Schering-Plough Corporation, and Sanofi-Aventis. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Vincent J. Milano , 45
Chairman, Chief Exec. Officer and Pres |
$
661.00K |
$
0 | Mr. Charles A. Rowland Jr. CPA MBA, 50
Chief Financial Officer and VP |
$
77.00K |
$
0 | Mr. Daniel B. Soland , 50
Chief Operating Officer, Chief Commercial Officer and VP |
$
522.00K |
$
0 | Dr. Colin Broom M.D., 53
Chief Scientific Officer and VP |
$
530.00K |
$
170.00K | Mr. Thomas F. Doyle , 48
VP of Strategic Initiatives |
$
474.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.11% Nasdaq 
0.62%
Profile
